Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Accumulated Depreciation & Amortization: 2011-2020

  • Neurocrine Biosciences' Accumulated Depreciation & Amortization rose 24.11% to $41.7 million in Q4 2020 from the same period last year, while for Dec 2020 it was $131.2 million, marking a year-over-year increase of 13.65%. This contributed to the annual value of $41.7 million for FY2020, which is 24.11% up from last year.
  • Per Neurocrine Biosciences' latest filing, its Accumulated Depreciation & Amortization stood at $41.7 million for Q4 2020, which was up 24.11% from $33.6 million recorded in Q4 2019.
  • In the past 5 years, Neurocrine Biosciences' Accumulated Depreciation & Amortization ranged from a high of $41.7 million in Q4 2020 and a low of $25.9 million during Q4 2016.
  • For the 3-year period, Neurocrine Biosciences' Accumulated Depreciation & Amortization averaged around $34.5 million, with its median value being $33.6 million (2019).
  • As far as peak fluctuations go, Neurocrine Biosciences' Accumulated Depreciation & Amortization dropped by 3.39% in 2016, and later climbed by 24.11% in 2020.
  • Quarterly analysis of 5 years shows Neurocrine Biosciences' Accumulated Depreciation & Amortization stood at $25.9 million in 2016, then increased by 6.28% to $27.6 million in 2017, then increased by 2.51% to $28.3 million in 2018, then rose by 18.85% to $33.6 million in 2019, then climbed by 24.11% to $41.7 million in 2020.
  • Its Accumulated Depreciation & Amortization was $41.7 million in Q4 2020, compared to $33.6 million in Q4 2019 and $28.3 million in Q4 2018.